OBI Pharma, Inc. (TPEX:4174)
Taiwan
· Delayed Price · Currency is TWD 62.00
+1.90 (3.16%)
Apr 2, 2025, 1:30 PM CST
OBI Pharma Revenue
In the year 2024, OBI Pharma had annual revenue of 62.68M TWD with 50.85% growth. OBI Pharma had revenue of 11.55M in the quarter ending December 31, 2024, a decrease of -37.30%.
Revenue
62.68M
Revenue Growth
+50.85%
P/S Ratio
231.05
Revenue / Employee
n/a
Employees
n/a
Market Cap
16.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.68M | 21.13M | 50.85% |
| Dec 31, 2023 | 41.55M | 36.84M | 781.96% |
| Dec 31, 2022 | 4.71M | -14.06M | -74.90% |
| Dec 31, 2021 | 18.77M | -122.11M | -86.68% |
| Dec 31, 2020 | 140.89M | 135.30M | 2,422.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Oneness Biotech | 117.93M |
| Lumosa Therapeutics | 39.15M |
| Pegavision | 6.82B |
| Polaris Group | 107.00M |